A. Shcherbina

发表

Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generation

Lia Gonçalves Pinho, Minghui He, C. Cunningham-Rundles, 2022 .

Clinical experience using selective immunomodulating targeted therapy of Interstitial lymphocytic lung disease in a group of pediatric patients with primary immunodeficiencies

Y. Rodina, G. Tereshenko, A. Rumiantsev, 2018 .

Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021

J. Casanova, A. Šedivá, Y. Rodina, 2022, Frontiers in Immunology.

Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity

Mark S. Anderson, J. Casanova, J. Fellay, 2022, Journal of Allergy and Clinical Immunology.

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency.

H. Reyburn, F. Hauck, S. Cowley, 2022, The Journal of allergy and clinical immunology.

Allogeneic Hematopoietic Stem Cell Transplantation Activity in Inborn Errors of Immunity in Russian Federation

Y. Skvortsova, I. Kondratenko, E. Skorobogatova, 2023, Journal of Clinical Immunology.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Mark S. Anderson, P. Gregersen, R. Nussbaum, 2021, Science Immunology.

Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency

Laura E. Covill, P. Gregersen, J. Casanova, 2022, The Journal of experimental medicine.

Activated Phosphoinositide 3-Kinase δ Syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

A. Schulz, V. Lougaris, A. Plebani, 2023, Journal of Allergy and Clinical Immunology.

Overactive WASp in XLN leads to aberrant B cell division and accelerated plasma cell generation.

Minghui He, C. Cunningham-Rundles, L. Hammarström, 2021, The Journal of allergy and clinical immunology.

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

J. Derisi, F. Rieux-Laucat, J. Fellay, 2023, Nature.

Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.

L. Alsina, A. Bolyard, S. Kiani-Alikhan, 2024, Blood.

Novel hemizygous CORO1A variant leads to combined immunodeficiency with defective platelet calcium signaling and cell mobility

A. Sveshnikova, M. Kurnikova, G. Novichkova, 2023, The journal of allergy and clinical immunology. Global.

Variants in the WDR44 WD40-repeat domain cause a spectrum of ciliopathy by impairing ciliogenesis initiation

S. Lalani, R. Louie, G. Chillemi, 2024, Nature communications.

Dissecting thrombus-directed chemotaxis and random movement in neutrophil near-thrombus motion in flow chambers.

A. Martyanov, A. Sveshnikova, E. Deordieva, 2024, BMC biology.